BR112021022347A2 - Processos e intermediários para a preparação de um inibidor de btk - Google Patents
Processos e intermediários para a preparação de um inibidor de btkInfo
- Publication number
- BR112021022347A2 BR112021022347A2 BR112021022347A BR112021022347A BR112021022347A2 BR 112021022347 A2 BR112021022347 A2 BR 112021022347A2 BR 112021022347 A BR112021022347 A BR 112021022347A BR 112021022347 A BR112021022347 A BR 112021022347A BR 112021022347 A2 BR112021022347 A2 BR 112021022347A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- intermediates
- processes
- btk inhibitor
- btk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019087823 | 2019-05-21 | ||
| PCT/EP2020/064123 WO2020234381A1 (en) | 2019-05-21 | 2020-05-20 | Processes and intermediates for preparing a btk inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112021022347A8 BR112021022347A8 (pt) | 2021-12-28 |
| BR112021022347A2 true BR112021022347A2 (pt) | 2022-01-04 |
Family
ID=70857160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022347A BR112021022347A2 (pt) | 2019-05-21 | 2020-05-20 | Processos e intermediários para a preparação de um inibidor de btk |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12215110B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3972977A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7658916B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220011668A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113874378A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020278162A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021022347A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3135240A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288154A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021014246A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020234381A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12450495B2 (en) | 2022-06-13 | 2025-10-21 | International Business Machines Corporation | Neural capacitance: neural network selection via edge dynamics |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2529621B1 (en) * | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| UY32531A (es) | 2009-03-31 | 2010-10-29 | Boehringer Ingelheim Int | Nuevos compuestos para el tratamiento de trastornos del snc |
| CN103121999A (zh) * | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
| EP2970291B1 (en) * | 2013-03-15 | 2022-05-11 | Janssen Pharmaceutica, N.V. | Processes and intermediates for preparing a medicament |
| US9156847B2 (en) | 2013-03-15 | 2015-10-13 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| MA41350A (fr) | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| RU2712440C2 (ru) | 2015-02-12 | 2020-01-29 | Шанхай Дьюд Медикал Сайенс Энд Текнолоджи Ко., Лтд | Способ получения ибрутиниба |
-
2020
- 2020-05-20 JP JP2021569238A patent/JP7658916B2/ja active Active
- 2020-05-20 BR BR112021022347A patent/BR112021022347A2/pt not_active IP Right Cessation
- 2020-05-20 CA CA3135240A patent/CA3135240A1/en active Pending
- 2020-05-20 AU AU2020278162A patent/AU2020278162A1/en not_active Abandoned
- 2020-05-20 EP EP20728440.7A patent/EP3972977A1/en active Pending
- 2020-05-20 KR KR1020217041326A patent/KR20220011668A/ko not_active Withdrawn
- 2020-05-20 US US17/612,082 patent/US12215110B2/en active Active
- 2020-05-20 MX MX2021014246A patent/MX2021014246A/es unknown
- 2020-05-20 CN CN202080037397.5A patent/CN113874378A/zh active Pending
- 2020-05-20 WO PCT/EP2020/064123 patent/WO2020234381A1/en not_active Ceased
-
2021
- 2021-11-16 IL IL288154A patent/IL288154A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113874378A (zh) | 2021-12-31 |
| AU2020278162A1 (en) | 2021-11-18 |
| MX2021014246A (es) | 2022-01-06 |
| BR112021022347A8 (pt) | 2021-12-28 |
| US12215110B2 (en) | 2025-02-04 |
| KR20220011668A (ko) | 2022-01-28 |
| US20220204516A1 (en) | 2022-06-30 |
| CA3135240A1 (en) | 2020-11-26 |
| IL288154A (en) | 2022-01-01 |
| WO2020234381A1 (en) | 2020-11-26 |
| JP7658916B2 (ja) | 2025-04-08 |
| JP2022533747A (ja) | 2022-07-25 |
| EP3972977A1 (en) | 2022-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022002375A2 (pt) | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl | |
| BR112018075433A2 (pt) | derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os | |
| BR112018001400A2 (pt) | compostos, processo para a síntese dos compostos, composição, utilização de um composto, método para o combate dos fungos e sementes | |
| UY30662A1 (es) | Método de cristalizacion discontinuo para cristalizar un anticuerpo anti-htnfalfa, cristales de anticuerpo obtenido por dicho método, composiciones que los conitenen y aplicaciones | |
| DOP2019000087A (es) | Compuestos químicos | |
| BR112022005472A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica | |
| BR112017007969A2 (pt) | método para produção de e-caprolactama | |
| BR112017028322A2 (pt) | compostos, processo para a produção de compostos i, para a produção de compostos ii dos compostos iii e para a produção de compostos iii, compostos intermediários v e utilização dos compostos i | |
| BR112015021856A2 (pt) | processos e intermediários para a preparação de um medicamento | |
| BR112018073490A2 (pt) | 6.7.beta-epóxidos esteroides como intermediários químicos | |
| BR112023024017A2 (pt) | Compostos, composição, método para combater fungos fitopatogênicos e semente | |
| BR112021026899A2 (pt) | Compostos heterocíclicos | |
| BR112018006519A2 (pt) | compostos de fórmula, processo para a síntese de compostos, compostos intermediários x, composição, utilização de um composto de fórmula, método para o combate de fungos e semente | |
| BR112016008354A2 (pt) | processo de preparação de alquilaluminoxanos por meio da reação de alquilalumínio com um álcool alílico substituído da fórmula, produto que pode ser obtido por meio do processo, e, uso do produto | |
| BR112019005886A2 (pt) | tratamento com água de material lipídico | |
| BR112022006052A2 (pt) | Processo para a preparação de protioconazol | |
| BR112023018654A2 (pt) | Compostos antibacterianos | |
| BRPI0816868A8 (pt) | Processo para a preparação de derivados de 2,2-difluoroetilamina, intermediários, seu uso e seu processo de preparação | |
| BR112023018655A2 (pt) | Compostos antibacterianos | |
| BR112014014604A2 (pt) | processo para a preparação de um composto, e, composto isolado e purificado | |
| BR112021020486A2 (pt) | Método para purificar toxina botulínica | |
| BR112021022347A8 (pt) | Processos e intermediários para a preparação de um inibidor de btk | |
| BRPI0816830A8 (pt) | Processo para a preparação de derivados de 2,2-diflúor-etilamina por hidrogenação de amida | |
| BR112022002815A2 (pt) | Método para preparar 2-(fenilimino)-3-alquil-1,3-tiazolidin- 4-onas | |
| CL2019000074A1 (es) | Método de producción de cristal de compuesto de uracilo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2881 DE 24-03-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |